MASLD: When Metabolic 'Fatty Liver' Becomes a Major Symptom of Energy Mismanagement

MASLD: When Metabolic 'Fatty Liver' Becomes a Major Symptom of Energy Mismanagement

by Laurent Glatz – for Athletic Carnivore

The New Name for an Old Metabolic Disorder

MASLD, or metabolic dysfunction-associated steatotic liver disease, is the updated term for what was previously known as non-alcoholic fatty liver disease. Simply put, it refers to an excessive accumulation of fat in the liver of a person exhibiting at least one significant metabolic dysfunction: abdominal overweight, insulin resistance, elevated blood sugar, type 2 diabetes, hypertension, or lipid abnormalities. This name change is not just semantic. It refocuses the issue on its true nature: modern fatty liver is not primarily about alcohol or a simple liver incident, but a direct expression of a systemic metabolic disorder. And this disorder is massive. In 2023, MASLD already affected approximately 1.3 billion people worldwide, with projections nearing 1.8 billion by 2050.

When the Liver Becomes the Hub of Energy Traffic

The physiological problem is simple in structure but formidable in consequences. When the body is under repeated glycemic pressure, with frequently elevated insulin, energy storage becomes the priority and metabolic flexibility declines. Adipose tissue poorly releases, poorly absorbs, and poorly signals. The liver, meanwhile, becomes the central hub. It receives, transforms, repackages, and stores. Some excess carbohydrates are converted into lipids through hepatic lipogenesis, while circulating fatty acids accumulate further in the context of insulin resistance. Popular belief still reduces fatty liver to vague caloric excess or a simple weight problem. Biology tells a different story: MASLD results from a faulty hormonal and energy partitioning, where insulin no longer regulates properly, blood sugar drifts, and storage overtakes oxidation.

Insulin, Leptin, Ghrelin, Cortisol: The Hormonal Disorder

The hormones involved paint a much clearer picture than usual nutritional recommendations. Insulin, when persistently elevated, promotes storage, inhibits fat utilization, and perpetuates the cycle of insulin resistance. Leptin, which should inform the brain that energy reserves are sufficient, loses effectiveness in many individuals with excessive adiposity: the body stores, but the brain no longer receives the message of sufficiency correctly. Ghrelin, the hunger hormone, then operates in an environment where satiety signals are blurred. Cortisol adds another layer of instability: when chronically elevated, it increases energy availability, disrupts blood sugar, disturbs metabolic balance, and fosters an environment conducive to hepatic fat accumulation. MASLD is therefore not just fat in the liver. It is the visible impact point of a hormonal system that has stopped finely regulating hunger, storage, inflammation, and energy availability.

From a Silent Signal to Systemic Disease

In the short term, this dysregulation already produces concrete effects: fatigue after meals, elevated triglycerides, increased waist circumference, unstable blood sugar, reduced true satiety, and progression of visceral fat. In the long term, the condition can escalate to a more severe inflammatory form, NASH (non-alcoholic steatohepatitis), then fibrosis, cirrhosis, liver failure, or hepatocellular carcinoma. MASLD is also closely linked to type 2 diabetes and cardiovascular risk, demonstrating it is never a local problem. This is precisely where current recommendations show inconsistencies: advice often remains vague—“eat balanced” or “move more”—while clinical reality demands a much stricter approach to glycemic load, frequency of insulin spikes, inflammation control, and restoration of satiety signals. A disease progressing alongside obesity, hyperglycemia, and diabetes calls not for slogans but for a cold, mechanistic understanding.

The Liver, a Witness Organ of Metabolic Collapse

The most disturbing point is this: metabolic fatty liver progresses not because the liver is fragile, but because the modern environment produces organisms unable to properly manage glucose, insulin, and storage. When a silent pathology closely follows the global rise in obesity and hyperglycemia, it ceases to be an individual anomaly. It becomes the biological mirror of a deeply incoherent dietary and metabolic model. The real question is not just what MASLD is. The real question is how much longer we will accept as “normal” a diet that pushes the body to store, inflame, and deregulate satiety—turning the liver into the witness organ of a general metabolic collapse.

#AthleticCarnivore #Carnivore #LowCarb #MetabolicHealth